Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Telix Pharmaceuticals Ltd Share Issue/Capital Change 2024

May 14, 2024

31324_rns_2024-05-14_86ebd9c9-8a45-4075-bd75-80038fc5f3d5.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday May 15, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred

Total number of
ASX +security +securities to be
code Security description issued/transferred Issue date
TLXAP SHARE RIGHTS 35,000 13/05/2024
TLXAO SHARE APPRECIATION RIGHTS 3,095,526 13/05/2024

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

1 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type Registration number ACN 616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

15/5/2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

2 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

3 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAP : SHARE RIGHTS

Date the +securities the subject of this notification were issued 13/5/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?
Yes
Provide details of the KMP or +associates being issued +securities.
Name of KMP
Name of registered holder
Number of +securities
Richard Valeix
Richard Valeix
35,000
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
or a summary of the terms
Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at
nancial-reports-presentations/

https://telixpharma.com/investor-centre/fi
Any other information the entity wishes to provide about the +securities the subject of this notification
The second tranche of Performance Share Rights (exercise price: nil) granted to Richard Valeix (CCO) as part of his sign
on to the CCO role as detailed in section 5.4.1 of the 2023 Remuneration report. Vesting is subject to achievement of the
performance conditions of the 2024 Long Term Variable Remuneration (LTVR).

Issue details

Number of +securities

35,000

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

13/5/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

4 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes

Provide details of the KMP or +associates being issued +securities.

Provide details of the KMP or +associates being issued +securities.
Name of KMP Name of registered holder Number of +securities
Darren Smith Darren Smith 50,874
Richard Valeix Richard Valeix 60,358
David Cade David Cade 49,461
Darren Patti Darren Patti 66,838

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at https://telixpharma.com/investor-centre/fi nancial-reports-presentations/

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (PSARs) (exercise price: $11.94) granted to Telix employees as 2024 Long Term Variable Remuneration (LTVR) as part of Total Target Remuneration Package for 2024. This includes Long Term Incentive PSARs granted to Darren Patti in relation to his role prior to being appointed as Group Chief Operating Officer. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2024-2026. For further details refer to the Remuneration report in Telix's 2023 Annual Report accessible at https://telixpharma.com/investor-centre/financial-reports-presentations/

Issue details

Number of +securities

3,095,526

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

5 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

Total number of
ASX +security code and description +securities on issue
TLX : ORDINARY FULLY PAID 330,455,778
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
Total number of
ASX +security code and description +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL 80,000
TLXAR : PERFORMANCE RIGHTS 2,523,720
TLXAP : SHARE RIGHTS 1,230,000
TLXAO : SHARE APPRECIATION RIGHTS 11,212,780
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37 584,492
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL 100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38 685,510
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS 440,000

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

6 / 7

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

7 / 7